drugset
drugset / Trial / NCT03450343

Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma

NCT03450343 ↗

Phase 1 Completed 9 enrolled Medical University of South Carolina Celgene Corporation · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety and tolerability of adding oral azacitidine to the chemotherapy combination R-ICE. This study will also look at whether or not disease outcomes improve with the combination.

Timeline

Start
2019-04-04
Primary completion
2023-08-31
Completion
2024-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacitidine Other / unclassified — Oral
Background Carboplatin Small molecule — —
Background Etoposide Small molecule — —
Background Ifosfamide Small molecule — —
Background Rituximab Monoclonal antibody — —

Indications

diffuse large B-cell lymphoma